drugset
drugset / Trial / NCT06183671

JX09 SAD/MAD in Healthy Participants

NCT06183671 ↗

Phase 1 Unknown 92 enrolled Ji Xing Pharmaceuticals Australia Pty Ltd Novotech (Australia) Pty Limited · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a phase 1, randomized, double-blind, placebo-controlled, multi-part, single and multiple ascending dose study in healthy adult to test the safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect of JX09 when administered to healthy adult subjects.

Timeline

Start
2024-01-18
Primary completion
2024-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject JX09 Unknown 1 mg Oral
Subject JX09 Unknown 2 mg Oral
Subject JX09 Unknown 3 mg Oral
Subject JX09 Unknown 5 mg Oral
Subject JX09 Unknown 10 mg Oral
Subject JX09 Unknown 20 mg Oral
Subject JX09 Unknown 30 mg Oral
Subject JX09 Unknown 100 mg Oral
Subject JX09 Unknown 300 mg Oral

Indications

resistant hypertension